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We show that the PARP in-
hibitor olaparib enhances
radiation-induced DNA
damage response in hypoxic
tumor cells of Calu-6 xeno-
grafts but not in nonhypoxic
tumor cells of Calu-6 xeno-
grafts or in tumor cells of
well-oxygenated Calu-3 xe-
nografts. Consequently, ola-
parib potentiates the
antitumor effect of radiation
in hypoxic tumors but not in
well-oxygenated tumors.
This suggests that hypoxia
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http://dx.doi.org/10.1016/j.ijrobp.2016.01.035Purpose: Poly(ADP-ribose) polymerase (PARP) inhibitors potentiate radiation therapy
in preclinical models of human non-small cell lung cancer (NSCLC) and other
types of cancer. However, the mechanisms underlying radiosensitization in vivo are
incompletely understood. Herein, we investigated the impact of hypoxia on
radiosensitization by the PARP inhibitor olaparib in human NSCLC xenograft models.
Methods andMaterials: NSCLCCalu-6 andCalu-3 cellswere irradiated in the presence
of olaparib or vehicle under normoxic (21% O2) or hypoxic (1% O2) conditions. In vitro
radiosensitivitywas assessed by clonogenic survival assay andgH2AX foci assay. Estab-
lished Calu-6 and Calu-3 subcutaneous xenografts were treatedwith olaparib (50mg/kg,
daily for 3 days), radiation (10 Gy), or both. Tumors (nZ3/group) were collected 24 or
72 hours after the first treatment. Immunohistochemistry was performed to assess hyp-
oxia (carbonic anhydrase IX [CA9]), vessels (CD31), DNA double strand breaks
(DSB) (gH2AX), and apoptosis (cleaved caspase 3 [CC3]). The remaining xenografts
(nZ6/group) were monitored for tumor growth.
Results: In vitro, olaparib showed a greater radiation-sensitizing effect in Calu-3 and
Calu-6 cells in hypoxic conditions (1% O2). In vivo, Calu-3 tumors were
well-oxygenated, whereas Calu-6 tumors had extensive regions of hypoxia associated
with down-regulation of the homologous recombination protein RAD51. Olaparib treat-
ment increased unrepaired DNADSB (P<.001) and apoptosis (P<.001) in hypoxic cells, CRUK & MRC Oxford
f Oncology, University of
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grafts by contextual syn-
thetic lethality.of Calu-6 tumors following radiation, whereas it had no significant effect on radiation-
induced DNA damage response in nonhypoxic cells of Calu-6 tumors or in the tumor
cells of well-oxygenated Calu-3 tumors. Consequently, olaparib significantly increased
radiation-induced growth inhibition in Calu-6 tumors (P<.001) but not in Calu-3 tumors.
Conclusions: Our data suggest that hypoxia potentiates the radiation-sensitizing effects
of olaparib by contextual synthetic killing, and that tumor hypoxia may be a potential
biomarker for selecting patients who may get the greatest benefit from the addition of
olaparib to radiation therapy.  2016 The Authors. Published by Elsevier Inc. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).Introduction
Non-small cell lung cancer (NSCLC), accounting for 80% to
85% of lung cancer cases, is the leading cause of
cancer-related death worldwide (1). A third of NSCLC pa-
tients are diagnosed at a locally advanced stage and radiation
therapy is amainstay for the treatment of these patients (2, 3).
Despite technical advances in radiation therapy, the local
tumor control remains suboptimal due to radioresistance
(4, 5). Because repair of DNA damage is a major cause of
radioresistance, inhibition of DNA repair represents a
rational strategy to enhance the efficacy of radiation therapy.
Poly(ADP-ribose) polymerase 1 (PARP-1) is a DNA
damageesensing protein. PARP-1 is activated upon binding
to DNA single-strand breaks (SSBs), whereupon it cata-
lyzes the production of poly(ADP-ribose) chains attached
to itself and other nearby proteins in order to facilitate DNA
repair (6). Thus this enzyme has been considered a prom-
ising target for radiosensitization. Indeed, PARP inhibition
has been shown to enhance the effects of radiation therapy
in various cell lines and several pre-clinical tumor types
including colon cancer (7, 8), prostate cancer (9), breast
cancer (10), and NSCLC (9-11). The mechanism for
radiosensitization by PARP inhibition in vitro is well
understood. PARP inhibitors prevent the release of PARP
from radiation-damaged DNA, thus DNA repair proteins
cannot access the SSBs. Unrepaired SSBs are converted
to lethal DNA double-strand breaks (DSBs) during
replication, thereby enhancing radiotoxicity (12).
Nevertheless, the underlying mechanisms of radio-
sensitization by PARP inhibition in vivo remain incom-
pletely understood. To date, few studies have looked at the
role of tumor microenvironment in radiosensitization by
PARP inhibition, although effects on the vasculature, such
as decreases in tumor vascular density (13) or tumor
vascular perfusion (11), have been implicated in
potentiation of radiation therapy by PARP inhibition in
lung cancer xenografts.
Tumor hypoxia is a major microenvironmental factor
that limits radiation therapy efficacy by decreasing
oxygen-mediated free radical damage (14). Chronic
hypoxia suppresses homologous recombination (HR)
protein expression and function in tumor cells (15, 16). AsHR is required for repair of DSBs that result from PARP
inhibition (17, 18), impaired HR can lead to unrepaired
DSBs and subsequently cell death. Therefore, hypoxia-
induced HR defects are considered synthetically lethal
with PARP inhibition (19, 20). This microenvironment-
mediated synthetic killing has been termed “contextual
synthetic lethality” (19). Such contextual synthetic lethality
might be synergistic with radiation. Despite several in vitro
studies showing that PARP inhibition radiosensitizes cells
under chronic hypoxia conditions (9, 20, 21), hypoxia has
not yet been directly linked to the radiosensitization by
PARP inhibition in solid tumors in vivo.
In this study,we sought to investigate the impact of hypoxia
on the radiosensitization by PARP inhibition in human
NSCLC xenograft tumors grown in nude mice. We assessed
the DNA damage response and tumor growth inhibition in
2 NSCLC xenograft models: Calu-6 xenografts (hypoxic)
andCalu-3 xenografts (well-oxygenated), following radiation
and the PARP1/2 inhibitor olaparib treatment.
Methods and Materials
Cell culture
Human lung carcinoma cells Calu-3, Calu-6, and A549
were purchased from the American Type Culture Collec-
tion. Cells were cultured in advanced Dulbecco’s modified
Eagle medium/F12 medium supplemented with 5% fetal
bovine serum, 2 mM glutamax, and 50 mg/mL penicillin/
streptomycin in a humidified atmosphere with 7.5% CO2.
In vitro gH2AX foci assay
The gH2AX foci assay was performed as previously
described (22). Briefly, cells were seeded into 96-well
plates and treated with 5 mmol/L olaparib or 0.05%
dimethyl sulfoxide (DMSO) 1 hour before irradiation (0 or
10 Gy) and then returned to the incubator for 24 hours
before fixation. Cells were fixed with 3% para-
formaldehyde, and blocked with 1% goat serum/1% bovine
serum albumin/0.1% Triton X-100 followed by incubation
with gH2AX antibody (1:1500 dilution; Millipore). Cells
were then washed and incubated with Alexa 488-labeled
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Hoechst (5 mg/mL; Sigma-Aldrich). The number of
gH2AX foci per nucleus was quantified from 400 nuclei
per well using the In Cell analyzer 1000 (GE Healthcare).
Clonogenic survival assays
Exponentially growing cells were seeded into 6-well plates,
and exposed to 21% O2 (normoxia) or 1% O2 (hypoxia) in a
Whitley H35 Hypoxystation (Don Whitley Scientific Ltd)
for 16 hours. An amount of 5 mmol/L olaparib (Selleck) or
0.05% DMSO was added to the medium 1 hour before
irradiation (0-6 Gy) with a cesium-137 source at
1.69 Gy/min (GSR D1 irradiator; Gamma Service Ltd)
under normoxic or hypoxic conditions. Twenty-four hours
after irradiation, cells were washed, and fresh medium was
added. Plates were incubated for 6 to 13 days to allow
colonies to form. Colonies were then fixed and stained with
0.5% crystal violet in 5% acetic acid and 75% methanol.
Colonies (50 cells) were counted. Clonogenic survival
curves and the sensitization enhancement ratio at 50%
(SER50) were generated using OriginPro version 8.5.1
software (OriginLab Corp).
Subcutaneous xenografts
All animal experiments were performed following local
ethical review under a project license from the UK Home
Office. Subject animals, 6- to 8-week-old female BALB/c
nude mice (Harlan Labs), were anesthetized with 2%
isoflurane. Calu-6 cells (2  106), Calu-3 cells (5  106), or
A549 cells (2  106) in 50% Matrigel (BD Biosciences)
were subcutaneously injected into a single site on the back
of the mouse. Mouse weights and tumor volumes were
measured 3 times each week (volume Z 1/2  length 
width  depth).
Tumor irradiation and treatment schedules
When xenografts reached 100 mm3, mice were randomized
to 1 of 4 groups (nZ12/group): (1) the vehicle group
(10% DMSO/10% captisol/PBS daily for 3 days by
intraperitoneal injection); (2) the olaparib group (olaparib
50 mg/kg daily for 3 days by intraperitoneal injection);
(3) the irradiation group (tumor-localized irradiation at a
single dose of 10 Gy [RS320 irradiation system;
1.82 Gy/min; Gulmay Medical Ltd) as previously described
(23); and (4) the combination group (olaparib 50 mg/kg
daily for 3 days, and tumor irradiation [10 Gy] given
30 minutes after the first dose of olaparib).
Three animals from each group were sacrificed at 24 or
72 hours after the first treatment, respectively, and tumors
were processed for immunohistochemistry (IHC). The
remaining animals (nZ6/group) were monitored for tumor
growth until the sizes of tumors reached 500 mm3 or 42 days
after initiation of treatment, whichever occurred first.Immunohistochemistry assay
Paraformaldehyde-fixed and paraffin-embedded tumor
sections were stained using EnVision G2 doublestain
system (Dako) according to the manufacturer’s instructions.
Antibodies used for immunohistochemistry were carbonic
anhydrase IX (CA9; 1:800 dilution; product AB1001; Bio-
Science), CD31 (1:50 dilution; product ab28364; Abcam),
GLUT1 (1:200 dilution; product ab14683; Abcam), RAD
51 (1:200 dilution; product GTX70230; GeneTex Inc),
gH2AX (1:1000 dilution; product 05-636; Millipore), and
cleaved caspase 3 (CC3; 1:600 dilution; product 9661; Cell
Signaling Technology). Staining for CC3, gH2AX, RAD51
(3,30-diaminobenzidine) and CA9 (Permanent Red) in
whole-tumor sections (excluding necrotic areas) was
analyzed using an Aperio CS scanner and ImageScope
analysis software (Aperio Technologies). Three tumor
samples were used per group. For gH2AX foci quantifi-
cation, 200 nuclei were assessed from each tumor sample.
EF5 binding was detected using the Cy3-conjugated anti-
body ELK3-51 (75 mM; University of Pennsylvania) as
described previously (24).
Statistical analysis
Data were expressed as means  SEM. Statistical analysis
was performed using Student t test (2-groups comparison)
or one-way ANOVA (more than 2 groups comparison) by
SPSS software (IBM). Statistical significance was defined
as P<.05.
Results
Olaparib enhances cytotoxic effects of radiation in
human NSCLC cells in vitro
The radiation-sensitizing effect of olaparib on normoxic
NSCLC cell lines in vitro was reported previously (11). To
assess whether olaparib affected DNA repair following
radiation, residual DNA DSBs in Calu-6 and Calu-3 cells
were quantified using a gH2AX foci immunofluorescence
assay (25) 24 hours after irradiation in the presence of
olaparib or vehicle (Fig. E1; available online at
www.redjournal.org). As expected, radiation alonemarkedly
increased the residual DNADSBs in both cell lines. Olaparib
alone also led to an increase in residual gH2AX foci for-
mation (P<.01). The combination treatment significantly
increased residual DNA DSBs compared with radiation
alone (P<.01), suggesting that olaparib compromises the
repair of radiation-induced DNA damage.
To further investigate the impact of oxygen on the
radiation-sensitizing potential of olaparib in NSCLC cell
lines, clonogenic survival assays were performed on
irradiated Calu-6 and Calu-3 cells in the presence of olaparib
or vehicle under 21% O2 (normoxic) or 1% O2 (hypoxic)
conditions. We observed a dose-dependent decrease of the
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Fig. 1. Olaparib radiosensitizes NSCLC cell lines in vitro. Calu-6 and Calu-3 cells were exposed to normoxia (21% O2) or
hypoxia (1% O2). Olaparib or vehicle was added to the medium 1 hour before radiation. At 24 hours after radiation, cells
were cultured in drug-free medium for clonogenic survival assays. (A) Clonogenic survival curves under normoxia.
(B) Clonogenic survival curves under hypoxia. Abbreviation: SER Z sensitization enhancement ratio.
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Although chronic hypoxic Calu-3 and Calu-6 cells were
slightly more radioresistant than normoxic cells, the
radiation-sensitizing effect of olaparib is greater under
chronic hypoxia (SER: 2.87  0.28 for Calu-3 and SER:
2.44  0.34 for Calu-6) than under normoxia (SER:
2.18  0.18 for Calu-3 and SER: 1.95  0.31 for Calu-6)
(Fig. 1A, B), suggesting that hypoxia induces contextual
synthetic lethality with PARP inhibition in vitro.Calu-6 xenografts have extensive hypoxic regions
To investigate the effects of hypoxia on radiosensitization
by olaparib in vivo, subcutaneous Calu-6 and Calu-3
xenografts were established, and tumor hypoxia was
assessed by IHC staining for CA9, a widely used intrinsic
marker for tumor hypoxia (26). The utility of CA9 as a
hypoxia marker was confirmed using another intrinsic
hypoxia marker GLUT1 and the extrinsic hypoxia marker
EF5 in sequential Calu-6 tumor sections. Good spatial
correlation was observed among CA9, GLUT1, and EF5
staining in Calu-6 xenograft tumors (Fig. E2; available
online at www.redjournal.org).Calu-6 tumors showed extensive plasma membrane
staining for CA9 in contiguous tumor cells bordering
regions of necrosis (Fig. 2A), with 12.1%  0.9% of cells
in Calu-6 tumors positively stained with CA9 (Fig. 2E),
demonstrating that Calu-6 tumors contain significant areas
of hypoxia. In contrast, CA9 staining was rarely seen in
Calu-3 xenograft tumor cells (Fig. 2B), with staining
evident only in occasional isolated cells. 1.7%  0.6% of
tumor cells in Calu-3 tumors were positively stained with
CA9 (Fig. 2E), indicating that Calu-3 xenograft tumors are
well-oxygenated. We have previously shown that Calu-6
xenografts are more poorly perfused than Calu-3
xenografts (23). Consistent with this, the blood vessels in
Calu-6 xenografts are sparse and embedded within tumor
cell mass surrounded by regions of hypoxia (Fig. 2C),
whereas there is a high density of blood vessels within the
stroma of nonhypoxic Calu-3 xenografts (Fig. 2D).RAD51 expression is down-regulated in hypoxic
regions of Calu-6 xenografts
Hypoxia can decrease HR protein expression. To explore
whether hypoxia-induced down-regulation of HR protein
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24 hours post-treatment were stained for RAD51 and
CA9 (Fig. 3A). The percentage of RAD51-positive
cells was significantly lower in CA9-positive areas
(hypoxic) compared with CA9-negative areas (non-
hypoxic) (P<.001), irrespective of treatment (Fig. 3B).Olaparib treatment increases unrepaired DNA DSBs
and apoptosis in hypoxic tumor cells of Calu-6
xenografts following irradiation
We next addressed the question of whether olaparib
exerted differential effects on radiation response in hyp-
oxic and nonhypoxic Calu-6 cells in vivo. gH2AX foci
levels were used as a surrogate of residual (unrepaired)DNA DSBs (27) and assessed by IHC 24 hours post-
treatment (Fig. 4A). As expected, radiation alone
induced a significant increase of gH2AX foci in CA9-
negative (nonhypoxic) cells (P<.001), but induced much
fewer foci in CA9-positive (hypoxic) cells (Fig. 4B).
Olaparib alone led to elevated gH2AX foci levels in CA9-
positive (hypoxic) cells (P<.05), but not in CA9-negative
cells (Fig. 4B). Surprisingly, when combined with
radiation, gH2AX foci were markedly increased in
CA9-positive (P<.001), but not in CA9-negative cells
compared with radiation alone. These data suggest that
olaparib selectively impacts the radiation-induced DNA
damage response in hypoxic cancer cells. We also
extended these data into another hypoxic NSCLC xeno-
graft model (A549) and showed that olaparib selectively
increased residual gH2AX foci in CA9-positive tumor
cells 24 hours after radiation (Fig. E3; available online at
www.redjournal.org).
Calu-6 tumors were stained for CC3, a protease
involved in programmed cell death and a cellular marker of
apoptosis (28) (Fig. 4C). Consistent with the gH2AX foci
data, radiation alone significantly increased the apoptosis
rate in CA9-negative cells (P<.001), but not in CA9-pos-
itive cells. Olaparib alone increased apoptosis rate in CA9-
positive cells (P<.05), and when in combination with
radiation, apoptosis was significantly enhanced in CA9-
positive cells (P<.001), but not in CA9-negative cancer
cells, compared with radiation alone (Fig. 4D). These data
suggest that olaparib enhances radiation-induced cell
killing through induction of apoptosis in hypoxic cancer
cells.
Olaparib does not enhance DNA damage response
to radiation in Calu-3 xenografts
Effects of olaparib on DNA damage response to radiation
were also assessed in Calu-3 xenografts. Since CA9 was
hardly detected in Calu-3 tumors, gH2AX foci and
apoptotic cells were only quantified in CA9-negative cells.
Twenty-four hours after treatment, olaparib showed no
effect on levels of gH2AX foci compared with
vehicle-treated controls, and there was no significant dif-
ference in the numbers of gH2AX foci and CC3-positive
cells between the radiation treatment group and the
combination treatment group (Fig. E4; available online at
www.redjournal.org). This finding, together with the data in
Calu-6 xenografts above suggests that olaparib does not
significantly affect the DNA damage response to radiation
in nonhypoxic cancer cells in vivo.
Olaparib treatment increases radiation-induced
growth inhibition in Calu-6 but not in Calu-3
xenografts
Given the finding that olaparib potentiated radiation-
induced DNA damage response in hypoxic Calu-6 tumor
BVehicle OlaparibA
0 
Gy
 
10
 G
y 
0 
Gy
 
10
 G
y 
C Vehicle Olaparib
0
2
4
6
8
10
CA9+ area  CA9- area
Av
er
ag
e 
nu
m
be
r 
of
 γh
2A
X 
fo
ci
/ 
nu
cl
eu
s 
Vehicle Olaparib 10 Gy Olaparib + 10 Gy
*
ns
ns
******
*
(Hypoxic) (Non-hypoxic)
D
0
5
10
15
20
25
30
CA9+ area  CA9- area
Pe
rc
en
ta
ge
 o
f 
CC
3-
po
si
ti
ve
 c
el
ls
 (
%
)
Vehicle Olaparib 10 Gy Olaparib + 10 Gy
*
***
ns
ns
(Hypoxic) (Non-hypoxic)
***
ns
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antitumor effect of radiation in NSCLC tumors. Compared
to Calu-3 tumors, Calu-6 tumors are more aggressive,
possibly associated with sustained tumor hypoxia. For
Calu-6 xenografts, olaparib alone had a small but
nonsignificant effect on tumor growth compared with
vehicle-treated controls (PZ.35, Fig. 5A). In combination
with radiation, tumor growth inhibition was significantly
enhanced compared with radiation alone (P<.001, Fig. 5A).
In Calu-3 xenografts, olaparib alone had no evident effect
on the tumor growth (PZ.39), and combination treatment
did not produce any greater antitumor effect than radiation
alone (PZ.53) (Fig. 5B). Therefore, olaparib was not
effective as a monotherapy, even in Calu-6 tumors that have
a significant proportion of hypoxic cells. However, our
results suggest that olaparib can act by selectively
increasing the antitumor effect of radiation in hypoxic
regions of tumors.Discussion
Although PARP inhibition has shown radiation-sensitizing
effects, the underlying mechanism in the context of hypoxia
in vivo has not yet been reported. Here, we show that
in vitro, radiation-sensitizing effect of olaparib was
greater under hypoxia than normoxia in both Calu-3 and
Calu-6 NSCLC cell lines. In vivo, olaparib increases
radiation-induced residual DNA DSBs and apoptosis in the
hypoxic tumor cells of Calu-6 xenografts, but not in the
nonhypoxic tumor cells of Calu-6 xenografts or in the
tumor cells of well-oxygenated Calu-3 xenografts. As a
result, olaparib potentiates antitumor effects of radiation inCalu-6 xenografts but not in Calu-3 xenografts. These
findings suggest that the radiosensitization by olaparib
in vivo may be due to hypoxia-induced contextual synthetic
killing.
Synergistic effects of PARP inhibitors in combination
with radiation therapy have been reported in human
NSCLC xenografts, including Calu-6, A549, and H460
xenografts (10, 11, 13). According to our own findings and
studies carried out by other groups (29, 30), these xenograft
models reported contain substantial regions of hypoxia,
whereas no previous work has investigated the effect of the
combination treatment in nonhypoxic NSCLC tumor
models in vivo. Barreto-Andrade et al (31) have noted that
PARP inhibition by ABT-888 enhances antitumor effects of
radiation in PC-3 prostate tumors but not in DU-145
prostate tumors, despite similar radiation sensitization
shown in both cell lines in vitro. Another study has shown
that the average hypoxic fraction of PC-3 xenografts (52%)
is higher than that of DU-145 xenografts (7%) (32), but this
aspect was not investigated by Barreto-Andrade et al (31) in
their study. Taken together, the published literature supports
our finding that the sensitizing effect of olaparib on
radiation is largely restricted to hypoxic regions of tumors.
RAD51 plays a central role in HR. In the present study,
we observed downregulation of RAD51 in hypoxic Calu-6
tumor cells in vivo. Our results are consistent with other
reports that have shown chronic hypoxia reduces HR
protein expression, leading to functional impairment of the
HR pathway of DNA DSB repair (15, 16, 33). Moreover, it
has been shown that radiosensitization by PARP inhibition
is more effective in DNA DSB repair-defective tumor cells
(34). Therefore, hypoxia-induced “contextual synthetic
lethality” can be synergistic with radiation.
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radiation-sensitizing effect under hypoxia than under
normoxia in vitro is in agreement with others’ finding (35).
However, no evidence of radiosensitization was observed
for nonhypoxic tumor cells in vivo. This discrepancy may
be due to the tumor microenvironmental factors that could
change the sensitivity of cells to olaparib combined with
radiation. In addition, in vitro data from other groups
suggest that the phase of the cell cycle affects PARP
inhibitioneinduced radiosensitization. Cells in S/G2
phases show greatest sensitivity to PARP inhibition
combined with radiation, whereas noncycling cells
exhibit minimal sensitivity (36, 37). It is possible that local
tumor microenvironment changed the proportion of the
proliferating versus nonproliferating tumor cells compared
with tumor cells grown in vitro, leading to a change in the
radiation-sensitizing effect. However, the underlying
mechanism may be more complex and will require further
studies.
Chan et al (19) previously showed that PARP inhibition
alone selectively killed hypoxic mouse embryonic
fibroblasts and thus proposed that PARP inhibitors might
be used as a monotherapy for hypoxic tumors. However, in
our study, although olaparib alone moderately enhanced
DNA damage response in hypoxic Calu-6 tumor cells, it
did not significantly inhibit tumor growth, suggesting
that the hypoxic fraction of the tumor was insufficient
to achieve a significant antitumor effect by olaparib
monotherapy.
Hypoxia contributes to aggressive tumor growth
(38, 39), and hypoxic cells are resistant to radiation (40).
Our data suggest that treatment-resistant hypoxic cells
can be targeted by using PARP inhibition in combination
with radiation therapy. Moreover, tumor hypoxia might be
predictive for antitumor effects of the combination
treatment. This will be particularly useful in lung
cancer treatment, as the oxygenation in lung cancer varies
(41, 42) and 25% of NSCLC cases can be defined as
highly hypoxic (43). Interestingly, a higher level of hypoxia
was found in squamous carcinoma, indicating this subtype
of NSCLC might respond well to the combination
treatment.
It is interesting to note that the levels of residual gH2AX
foci and apoptosis in Calu-3 tumors were lower than Calu-6
tumors following radiation. We and others have previously
shown that Calu-3 and Calu-6 xenograft models display
different stromal phenotypes (23, 44), which might result in
differential DNA damage response to radiation in Calu-3
and Calu-6 xenografts.
In this study, we used CA9 immunostaining as a marker
for hypoxia, which correlated with EF5 staining.
Noninvasive in vivo imaging of hypoxia using hypoxic
specific PET radiotracers, such as [18F]FMISO, [18F]FAZA,
and [18F]EF5 (45), are potential modalities for patient
selection. In addition, a recently developed in vivo hypoxia
metagene signature might provide another method to
identify hypoxic tumors (46, 47).Conclusions
In conclusion, our study suggests that hypoxia potentiates
radiation-sensitizing effects of PARP inhibitor olaparib by
contextual synthetic lethality. Tumor hypoxia may be a
potential predictive biomarker that could identify the subset
of patients who would benefit most from a combination
treatment of olaparib and radiation therapy.References
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